The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer Who Received Prior Androgen Deprivation Therapy and Reached Low Prostate-Specific Antigen Levels Treated Further With Enzalutamide: Post Hoc Analyses of ARCHES
Patient-Reported Quality of Life in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole: Results From PALOMA-4
September 11, 2022 ESMO 2022 Prostate Cancer